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Abstract
Background: Switch therapy is a management approach combining early discontinuation of intravenous (IV)
antibiotics, switch to oral antibiotics, and early hospital discharge. This analysis compares switch therapy using
tigecycline versus levofloxacin in hospitalized patients with community-acquired pneumonia (CAP).
Methods: A prospective, randomized, double-blind, Phase 3 clinical trial; patients were randomized to IV tigecycline
(100 mg, then 50 mg q12h) or IV levofloxacin (500 mg q24h). Objective criteria were used to define time to switch
therapy; patients were switched to oral levofloxacin after ≥6 IV doses if criteria met. Switch therapy outcomes were
assessed within the clinically evaluable (CE) population.
Results: In the CE population, 138 patients were treated with IV tigecycline and 156 were treated with IV
levofloxacin. The proportion of the population that met switch therapy criteria was 67.4% (93/138) for tigecycline
and 66.7% (104/156) for levofloxacin. The proportion that actually switched to oral therapy was 89.9% (124/138) for
tigecycline and 87.8% (137/156) for levofloxacin. Median time to actual switch therapy was 5.0 days each for
tigecycline and levofloxacin. Clinical cure rates for patients who switched were 96.8% for tigecycline and 95.6% for
levofloxacin. Corresponding cure rates for those that met switch criteria were 95.7% for tigecycline and 92.3% for
levofloxacin.
Conclusions: Switch therapy outcomes in hospitalized patients with CAP receiving initial IV therapy with tigecycline
are comparable to those of patients receiving initial IV therapy with levofloxacin. These data support the use of IV
tigecycline in hospitalized patients with CAP when the switch therapy approach is considered.
ClinicalTrials.gov Identifier: NCT00081575
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Background
Community-acquired pneumonia (CAP), one of the most
common infectious diseases managed by clinicians, is a
key source of morbidity, mortality and expenditure of
health-care resources [1,2]. Empiric antimicrobial recom-
mendations, aimed at use of “correct-spectrum” cover-
age, are outlined in guidelines adopted by numerous
global agencies [3-10], including evidence-based guidelines
from the Infectious Diseases Society of America and the
American Thoracic Society (IDSA/ATS) [11]. Yet, a re-
cent compliance evaluation conducted in 36 hospitals in
14 countries found that practitioners do not routinely
follow the guidelines; improvement is needed, especially
in the areas of CAP prevention, initial empirical therapy,
and switch from intravenous (IV) to oral antibiotics [12].
Identifying patients who may be candidates for early
switch from IV to oral antibiotic therapy and potentially
early hospital discharge is important in the management
of CAP [12-14]. Switch therapy is generally considered
appropriate and safe when four criteria indicative of clin-
ical stability are met, including improvement in cough
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and respiratory distress-related symptoms, defervescence
of fever for at least 8 hours, normalizing white blood cell
count, and adequate oral intake and gastrointestinal tract
absorption. The majority of patients with non-severe dis-
ease can switch from IV to oral therapy within 2–4 days.
Previous prospective studies of hospitalized CAP patients
have shown that clinical cure rates with switch therapy
were high [15-17], even in patients whose pneumonia is
complicated by bacteremia [18]. Switch therapy also has
health economic benefits via reduction in costs due to
drug administration and decreased length of hospital
stay [13].
Tigecycline is a first-in-class expanded broad-spectrum,
glycylcycline antibiotic [19], and is approved by the U.S.
FDA for the treatment of community-acquired bacterial
pneumonia caused by penicillin-susceptible Streptococcus
pneumoniae, beta-lactamase negative Haemophilus influ-
enzae, and Legionella pneumophila. Tigecycline is well
distributed into lung tissues and fluids [20], and has been
shown to be as effective as levofloxacin in two global
Phase 3 clinical trials of CAP [21].
In the current analysis, data from one of the pivotal
prospective trials that compared the efficacy of tigecy-
cline vs. levofloxacin in hospitalized patients with CAP
[22] was used to assess outcomes in patients switched to
oral therapy. The primary objectives of this study were
1) to compare clinical cure rates for hospitalized patients
with CAP treated empirically with IV tigecycline followed
by a switch to oral levofloxacin versus those treated empir-
ically with IV levofloxacin followed by a switch to oral
levofloxacin and 2) to compare time to switch therapy
for hospitalized patients with CAP treated empirically
with IV tigecycline versus those treated empirically with
IV levofloxacin.
Methods
Study design and treatment
A detailed description of the patients and methodology
for tigecycline study 308 are described elsewhere [22]. In
brief, a Phase 3, multicenter, randomized, double-blind
(third party unblinded) clinical trial was conducted to
compare the efficacy and safety of tigecycline with levo-
floxacin in hospitalized adults with CAP. The current
analysis focused on comparing efficacy outcomes for two
subgroups of patients: those receiving oral switch ther-
apy and those not switched to an oral antibiotic.
Patients were randomly assigned (1:1) to initially re-
ceive either IV tigecycline (100 mg initially followed by
50 mg every 12 h) or IV levofloxacin (500 mg every 24 h)
[22]. A reduced dose of levofloxacin was given to pa-
tients with impaired renal function. After at least 3 days
of IV therapy (6 IV doses), patients in either treatment
group could be switched to oral levofloxacin treatment
(500 mg every 24 h), at the investigator's discretion, after
meeting specified criteria (see below). The total duration
of study therapy was 7 to 14 days at the investigator’s
discretion.
Patient eligibility
Hospitalized adult patients (at least 18 years of age) of ei-
ther gender with CAP who initially required IV antibio-
tics could participate. Each patient had a documented
fever within 24 h of enrolment, a new lung infiltrate con-
firmed by chest radiograph within 48 h of receiving the
first dose of study medication and at least 2 common
signs and/or symptoms suggestive of CAP (e.g., cough,
production of purulent sputum, WBC>10 × 109/L). Pa-
tients were not allowed to participate in the study for
any of the following reasons: recent hospitalization
within 14 days, residence in a long-term care facility for
≥14 days before onset of symptoms, required treatment
in the ICU at the time of randomization, and those with
known or suspected Pseudomonas aeruginosa infection.
Oral switch criteria
In study 308, the specific criteria listed below were to be
satisfied at the time the patient was switched to oral
levofloxacin. The improvements in signs and symptoms
of pneumonia (e.g., cough, shortness of breath, tem-
perature) were to be interpreted by the investigator in re-
lation to the prior day, not baseline. The specific criteria,
as judged by the investigator, indicating that clinical sta-
bility had been achieved and that the patient was a can-
didate for oral therapy included the following:
1. Cough and shortness of breath improving.
2. Patient afebrile for ≥24 hours (oral temperature
<37.8°C/100°F, or equivalent for axillary, tympanic,
or rectal/core temperature), on 2 or more
measurements at least 24 hours apart, with no
known spiking of temperature during that interval.
3. White blood cell count improving (no change was
required if the WBC count was within normal
range): >10% decrease if initial WBC count was
elevated (>10 × 109/L); >5% decrease in immature
neutrophils (bands) if initially >15%; or >10%
increase if patient was initially leukopenic (WBC
<4.5 × 109/L).
4. Oral intake and gastrointestinal tract absorption
adequate.
Oral intake was defined as a patient taking food by
mouth without gastrointestinal intolerance on any day.
For the other three objective criteria of WBC count,
cough/dyspnea, and temperature, the patient was consid-
ered to reach criteria based on change from baseline or
the prior day. In this analysis, patients had to meet all
three objective criteria and oral intake criteria to be
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considered a candidate for oral therapy. For WBC, pa-
tients could meet any of the criteria below, up to the last
day of therapy visit:
 Previous WBC is normal and first WBC value
post-baseline is normal
 Previous WBC is above normal and WBC decreases
by 10% (second value)
 Previous WBC is below normal and WBC increases
by 10% (second value)
 If previous bands >15% and bands decrease by 5%
(second value)
For cough and dyspnea, patients could meet any of the
criteria below from the first visit up to last day of therapy
visit:
 Cough and dyspnea are absent
 Cough and dyspnea improve from the previous visit
(second visit)
 Cough and dyspnea are unchanged from previous
visit and improved from baseline
For temperature, patient met criteria if temperature
was <37.8 °C with a previous temperature <37.8 °C (sec-
ond visit). If multiple temperatures were taken during
same relative day, the maximum temperature was used.
Time to clinical stability
Patients were considered to have clinical improvement
on the day they met all 4 criteria for switch therapy
according to the study protocol. Patients who satisfied
the criteria for switch therapy during the first 3 days of
hospital treatment were considered to have early clinical
stability. Patients who met the criteria for switch therapy
from days 4 to 7 of hospital treatment were considered
to have late clinical stability.
Analysis population and efficacy assessments
The present analysis is restricted to patients categorized
as clinically evaluable (CE). Patients who had clinical evi-
dence of CAP by meeting the minimal disease criteria
were considered to be CE if they satisfied inclusion and
exclusion criteria, received no more than one dose of a
non-once, daily, non-study antibacterial agent (single agent
or combination therapy) to treat the current episode of
CAP before the first dose of study drug, did not receive
other concomitant systemic antimicrobial therapy unless
a treatment failure, received at least 2 full days of study
drug if clinical failure or 5 full days of study drug (IV
plus oral) if clinical cure, were adherent with therapy (i.e.,
≥80%, but ≤120% of medication administered), had an
assessment of cure or failure (and not indeterminate) at
the test-of-cure (TOC) visit, and the study blind was
maintained. The primary efficacy endpoint was clinical
response in the CE population at the TOC visit.
Statistical analysis
Categorical baseline demographic and medical variables
were analyzed using Fisher’s exact test and chi-square
test. Continuous variables were compared using a one-
way analysis of variance (ANOVA) model with treatment
as a factor. The time to meet oral switch criteria was
analyzed by the Kaplan-Meier approach using log-rank
test for differences in survival curves.
Overall clinical response rates were compared for hos-
pitalized patients with CAP treated empirically with IV
tigecycline followed by a switch to oral levofloxacin ver-
sus those treated empirically with IV levofloxacin fol-
lowed by a switch to oral levofloxacin, using Fisher’s
exact test. Clinical response was also evaluated for each
treatment for patients in the following groups: IV/PO
Switch (all patients who switched to PO therapy) versus
IV-only (patients not switched to PO therapy) and Met
Switch Criteria (regardless of whether the patient was
switched to oral therapy) versus Did Not Meet Switch Cri-
teria. P values <0.05 were considered significant. Statis-
tical analysis was performed by the Global Biostatistics
and Programming department of Wyeth Research, Colle-
geville, PA, which was acquired by Pfizer Inc in October
of 2009.
The study protocol was reviewed and approved by
each investigator's independent ethics committee or in-
stitutional review board in accordance with local reg-
ulations and good clinical practices. Written informed
consent was obtained from each patient or his or her
guardian before initiation of any study procedure ac-
cording to the guidelines of each institution.
Results
Patients and treatment
A total of 425 patients were available for the Intent To
Treat population analysis in study 308. A total of 294
patients were included in the CE population. The CE
population was comprised of 138 hospitalized patients
with CAP treated empirically with IV tigecycline and 156
hospitalized patients with CAP treated empirically with
IV levofloxacin (Table 1). Nearly two-thirds (67.0%; [197/
294]) of patients met objective IV to oral switch criteria
per study protocol (93/138, 67.4% tigecycline and 104/156,
66.7% levofloxacin; Table 1). Switch to oral therapy was
performed in 88.8% (261/294) of patients (124/138,
89.9% tigecycline; 137/156, 87.8% levofloxacin; Table 1).
Demographic and baseline medical characteristics,
grouped by patients who were switched or not switched
to oral therapy, are outlined in Table 2.
The median time to clinical stability (i.e., time when all
criteria for oral switch were met) for the CE population
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was 4 days each for tigecycline and levofloxacin
(P = 0.220; Figure 1). Nearly 50% of patients in both
treatment groups were categorized as having early
clinical stability. The median time to actual switch to
oral therapy was 5.0 days each for tigecycline- and
levofloxacin-treated patients (P=0.274; Figure 2). Figure 3
illustrates the number of patients in each group who met
IV to oral switch criteria, as determined by the present
analysis, by treatment day. Of note, 64 patients who were
switched to oral therapy (31 tigecycline, 33 levofloxacin)
had not met objective criteria for IV to oral switch, as
determined by the present analysis. Thirteen patients
who met objective criteria for IV to oral switch were not
switched to oral therapy (4 tigecycline, 9 levofloxacin).
Although the study protocol had easy to follow and well-
defined switch therapy criteria, in 77 of the 294 patients
evaluated (26%), the switch therapy criteria were not fol-
lowed by the investigators.
Clinical efficacy
For patients switched to oral therapy by the investigator,
overall cure rates in the CE population were similar be-
tween tigecycline and levofloxacin (tigecycline 96.8%
[120/124]; levofloxacin 95.6% [131/137]) (P= 0.752; Fig-
ure 4). In patients not switched, cure rates were low, as
expected, in both treatment groups (tigecycline 35.7% [5/
14]; levofloxacin 26.3% [5/19]) (P= 0.707). Among pa-
tients who met switch criteria as determined by the study
protocol, the clinical cure rate was 95.7% (89/93) for tige-
cycline and 92.3% (96/104) for levofloxacin (P= 0.382;
Figure 4). Corresponding rates for patients who did not
meet switch criteria were 80.0% (36/45) and 76.9% (40/
52), respectively (P= 0.807).
Discussion
This study indicates no significant difference in the clin-
ical cure rates for hospitalized patients with CAP treated
Table 1 Clinically Evaluable Population
Number of patients, n (%) Tigecycline (N=138) Levofloxacin (N= 156) Total (N = 294)
Patients switched to oral therapy 124 (89.9%) 137 (87.8%) 261 (88.8%)
Patients not switched to oral therapy 14 (10.1%) 19 (12.2%) 33 (11.2%)
Patients meeting switch criteria as determined by present analysis 93 (67.4%) 104 (66.7%) 197 (67.0%)
Patients not meeting switch criteria as determined by present analysis 45 (32.6%) 52 (33.3%) 97 (33.0%)
Patients switched without meeting switch criteria as determined by present analysis 31 (22.5%) 33 (21.2%) 64 (21.8%)
Table 2 Baseline Demographic and Medical Characteristics for CE Population: Switched vs. Not Switched from IV to
Oral Therapy
Characteristic
Switched (IV to oral) No Switch (IV only)
Tigecycline N= 124 Levofloxacin N= 137 P-value Tigecycline N= 14 Levofloxacin N=19 P-value
Age, yrs, mean±SD 55.2 ±16.4 54.0 ± 20.4 0.613 60.1 ± 18.1 63.1 ± 17.2 0.634
Male, n (%) 64 (51.6) 83 (60.6) 0.145 9 (64.3) 13 (68.4) 0.803
Ethnic origin, n (%) 0.189 0.620
White 80 (64.5) 87 (63.5) 9 (64.3) 9 (47.4)
Hispanic 29 (23.4) 34 (24.8) 5 (35.7) 7 (36.8)
Black 14 (11.3) 9 (6.6) 0 1 (5.3)
Asian 0 4 (2.9) 0 1 (5.3)
Other 1 (0.8) 3 (2.2) 0 1 (5.3)
Fine Score, n (%) 0.452 0.816
I 28 (22.6) 41 (29.9) 3 (21.4) 2 (10.5)
II 43 (34.7) 42 (30.7) 1 (7.1) 1 (5.3)
III 33 (26.6) 29 (21.2) 5 (35.7) 7 (36.8)
IV 20 (16.1) 25 (18.2) 5 (35.7) 9 (47.4)
Prior antibiotic failure, n (%) 2 (1.6) 4 (3.0) 0.471 0 1 (5.3) 0.383
Therapy duration, days, mean±SD 11.39 ± 2.0 11.26 ± 2.0 0.599 6.7 ± 3.1 6.3 ± 3.7 0.746
Presence of multilobar infiltrates, n (%) 32 (25.8) 22 (16.1) - 7 (50.0) 7 (36.8) -
Presence of altered mental status, n (%) 2 (1.6) 5 (3.6) - 0 1 (5.3) -
Ramirez et al. BMC Infectious Diseases 2012, 12:159 Page 4 of 7
http://www.biomedcentral.com/1471-2334/12/159
empirically with IV tigecycline followed by a switch to
oral levofloxacin versus those treated empirically with IV
levofloxacin followed by a switch to oral levofloxacin.
There was also no significant difference in the time to
switch therapy for hospitalized patients with CAP treated
empirically with IV tigecycline versus those treated em-
pirically with IV levofloxacin. The median time to meet
criteria for switch therapy was 4 days for both study
groups. Our study findings indicating equal clinical activ-
ity and equal time to switch therapy for each study arm
suggest that both antibiotics have similar activity against
pulmonary pathogens.
Nearly half of all hospitalized patients with CAP met
criteria for switch therapy by day 3 of hospitalization.
These data indicating early clinical stability in a signifi-
cant number of hospitalized patients with CAP, are simi-
lar to those reported in prior studies on CAP [15-18]. It
is important to recognize these groups of patients with
early clinical improvement since they can be targeted for
an approach for early switch therapy and early hospital
discharge. National guidelines indicate that patients can
be safely switched to oral therapy on the same day they
meet criteria for clinical stability. In our study, the me-
dian time for patients to meet criteria for clinical stability
was 4 days in both study arms, but the time to actual
switch was 5 days in both study arms. This one-day delay
Figure 1 Days until patients met objective criteria for IV to oral
switch.
Figure 2 Days until patients actually switched from IV to oral
therapy.
Figure 3 Number of patients meeting objective IV to oral
switch criteria.
Figure 4 Clinical cures.
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to implement oral switch will not offer any clinical bene-
fit and is likely to delay hospital discharge. A delayed
switch to oral therapy may also be associated with a
number of potential detrimental effects to the patient,
the caregiver, and the healthcare system. Although our
analysis did not capture these parameters, delayed hos-
pital discharge may increase the patient's risk for nosoco-
mial infections [16].
Our data indicate that patients who were less severely
ill (e.g., Fine Score I-III) were more likely to reach cri-
teria for switch therapy. These findings are in agreement
with a recent evaluation of severity of disease at time of
hospitalization and time to clinical stability for patients
with CAP [23]. The authors found that as severity of dis-
ease increased, measured by CRB-65 and Fine Score,
time to clinical stability also increased.
This study has several limitations. Although the protocol
defined objective criteria for switch therapy, the actual
switch to oral therapy was at the discretion of the investi-
gator. The fact that, in 26% of the patients the investiga-
tors failed to follow the switch therapy criteria as defined
in the protocol, has the potential to induce selection bias.
As explained in the Methods section, we used only the
clinically evaluable population for our analysis. Since we
did not use the Intent To Treat population, this may have
incorporated some bias into the results. The study did not
collect long-term efficacy data beyond the test of cure visit
at 7-23 days after the last day of antibiotic therapy. Be-
cause of the short follow-up in some patients there is a
possibility for missing cases with relapse of infection after
switch. In this study, we evaluated the role of two antibio-
tics in time to clinical stability. Confounding factors for
this association include the bacterial etiology of CAP
as well as host factors. The generalizability of our data
is limited due to the fact that patients admitted to the
ICU or patients with risk factors for Pseudomonas aerugi-
nosa were excluded from the trial. One strength of this
study is that randomization into the two study arms may
limit confounding effects.
Because duration of hospitalization is an important
driver in the costs of CAP, implementing an oral switch
protocol will provide economic benefits. Although not
all patients who are candidates for oral switch therapy
can be discharged early, adoption of universal switch
therapy in the U.S. is estimated to reduce hospital days
by more than a half a million days annually with an over-
all savings in excess of $400 million [13]. Adoption of an
oral switch strategy is also an important component of
antibiotic stewardship programs, which are aimed, in
part, at minimizing emergence of multiple-drug resistant
bacteria [24-26]. Despite data that support the efficacy of
oral switch therapy [15-18, 27-30], practitioners often fail
to assess if a patient is an appropriate candidate, or elect
to continue IV therapy because the patient is improving.
Conclusion
In conclusion, the tigecycline approach to switch therapy
is equivalent to a levofloxacin approach to switch ther-
apy. This study supports the use of short-course tigecy-
cline in hospitalized patients with community-acquired
pneumonia followed with an early switch to oral therapy
in appropriate patients.
Competing interests
AC is an employee of Pfizer Inc. DG and TB are former employees of Pfizer,
Inc. JAR is on the Speakers’ Bureau for Pfizer Inc. TW has no conflicts to
report.
Author contributions
JAR: Contributed to protocol development, data analysis, manuscript
development and critical review. ACC: Contributed to protocol development,
data analysis, manuscript development and critical review. TW: Contributed
to data analysis, manuscript development and critical review. DG:
Contributed to protocol development, data analysis, manuscript
development and critical review. TB: Contributed to protocol development,
data analysis, manuscript development and critical review. All authors read
and approved the final manuscript.
Acknowledgments
The original study and the present analysis were sponsored and supported
by Wyeth Research, Collegeville, PA, USA, which was acquired by Pfizer Inc in
October 2009. The authors thank Dr. Gary Dukart, formerly of Pfizer Inc., for
his invaluable contributions to the present study and analysis, as well as to
the preparation of this manuscript. Editorial support for the preparation of
this manuscript, funded by Pfizer Inc., was provided by Annie Jones of
Upside Endeavors, LLC (Sanatoga, PA) and Patricia Fonseca of UBC Scientific
Solutions (Horsham, UK).
Author details
1University of Louisville, Louisville, KY, USA. 2Pfizer Inc, Collegeville, PA, USA.
3Division of Infectious Diseases, University of Louisville, 501 E Broadway Suite
308, Louisville, KY 40202, USA.
Received: 6 October 2011 Accepted: 8 March 2012
Published: 19 July 2012
References
1. Carbonara S, Monno L, Longo B, Angarano G: Community-acquired
pneumonia. Curr Opin Pulm Med 2009, 15(3):261–273.
2. Niederman MS: Community-acquired pneumonia: the U.S. perspective.
Semin Respir Crit Care Med 2009, 30(2):179–188.
3. Mandell LA, Marrie TJ, Grossman RF, Chow AW, Hyland RH: Summary of
Canadian Guidelines for the Initial Management of Community-acquired
Pneumonia: An evidence-based update by the Canadian Infectious
Disease Society and the Canadian Thoracic Society. Can J Infect Dis. 2000,
11(5):237–248.
4. Miyashita N, Matsushima T, Oka M, Japanese Respiratory Society: The JRS
guidelines for the management of community-acquired pneumonia in
adults: an update and new recommendations. Intern Med 2006,
45(7):419–428.
5. Niederman MS: Review of treatment guidelines for community-acquired
pneumonia. Am J Med 2004, 117(Suppl 3A):51S–57S.
6. Woodhead M: Community-acquired pneumonia guidelines–an
international comparison: a view from Europe. Chest 1998,
113(3 Suppl):183S–187S.
7. Woodhead M, Macfarlane J: Local antibiotic guidelines for adult
community-acquired pneumonia (CAP): a survey of UK hospital practice
in 1999. J Antimicrob Chemother 2000, 46(1):141–143.
8. British Thoracic Society Standards of Care Committee (2001): BTS Guidelines
for the Management of Community Acquired Pneumonia in Adults.
Thorax 2001, 56(Suppl 4):IV1–64.
9. Memish ZA, Shibl AM, Ahmed QA: Guidelines for the management of
community-acquired pneumonia in Saudi Arabia: a model for the Middle
East region. Int J Antimicrob Agents 2002, 20(Suppl 1):S1–S12.
Ramirez et al. BMC Infectious Diseases 2012, 12:159 Page 6 of 7
http://www.biomedcentral.com/1471-2334/12/159
10. Gialdroni Grassi G, Bianchi L: Guidelines for the management of
community-acquired pneumonia in adults. Italian Society of
Pneumology. Italian Society of Respiratory Medicine. Italian Society of
Chemotherapy. Monaldi Arch Chest Dis 1995, 50(1):21–27.
11. Mandell LA, Wunderink RG, Anzueto A, Bartlett JG, Campbell GD, Dean NC,
et al: Infectious Diseases Society of America/American Thoracic Society
consensus guidelines on the management of community-acquired
pneumonia in adults. Clin Infect Dis 2007, 44(Suppl 2):S27–S72.
12. Ramirez JA: Worldwide perspective of the quality of care provided to
hospitalized patients with community-acquired pneumonia: results from
the CAPO international cohort study. Semin Respir Crit Care Med 2005, 26
(6):543–552.
13. Ramirez JA: Managing antiinfective therapy of community-acquired
pneumonia in the hospital setting: focus on switch therapy.
Pharmacotherapy 2001, 21(7 Pt 2):79S–82S.
14. Peyrani P, Christensen D, LaJoie AS, Nakamatsu R, Arnold F, Schulz P, et al:
Antibiotic therapy of hospitalized patients with community-acquired
pneumonia: an international perspective from the CAPO Cohort Study.
J Ky Med Assoc 2006, 104(11):513–517.
15. Ramirez JA, Vargas S, Ritter GW, Brier ME, Wright A, Smith S, et al: Early
switch from intravenous to oral antibiotics and early hospital discharge:
a prospective observational study of 200 consecutive patients with
community-acquired pneumonia. Arch Intern Med 1999,
159(20):2449–2454.
16. Ramirez JA: Switch therapy in community-acquired pneumonia.
Diagn Microbiol Infect Dis 1995, 22(1–2):219–223.
17. Ramirez JA, Srinath L, Ahkee S, Huang A, Raff MJ: Early switch from
intravenous to oral cephalosporins in the treatment of hospitalized
patients with community-acquired pneumonia. Arch Intern Med 1995, 155
(12):1273–1276.
18. Ramirez JA, Bordon J: Early switch from intravenous to oral antibiotics in
hospitalized patients with bacteremic community-acquired
Streptococcus pneumoniae pneumonia. Arch Intern Med 2001,
161(6):848–850.
19. McKeage K, Keating GM: Tigecycline: in community-acquired pneumonia.
Drugs 2008, 68(18):2633–2644.
20. Conte JEJ, Golden JA, Kelly MG, Zurlinden E: Steady-state serum and
intrapulmonary pharmacokinetics and pharmacodynamics of tigecycline.
Int J Antimicrob Agents 2005, 25(6):523–529.
21. Tanaseanu C, Bergallo C, Teglia O, Jasovich A, Oliva ME, Dukart G, et al:
Integrated results of 2 phase 3 studies comparing tigecycline and
levofloxacin in community-acquired pneumonia. Diagn Microbiol Infect Dis
2008, 61(3):329–338.
22. Bergallo C, Jasovich A, Teglia O, Oliva ME, Lentnek A, de Wouters L, et al:
Safety and efficacy of intravenous tigecycline in treatment of
community-acquired pneumonia: results from a double-blind
randomized phase 3 comparison study with levofloxacin.
Diagn Microbiol Infect Dis 2009, 63(1):52–61.
23. Arnold FW, Brock GN, Peyrani P, Rodriguez EL, Diaz AA, Rossi P, Ramirez JA:
Predictive accuracy of the pneumonia severity index vs CRB-65 for time
to clinical stability: Results from the Community-Acquired Pneumonia
Organization (CAPO) International Cohort Study. Respir Med 2010, 104
(11):1736–1743.
24. Antibiotic stewardship programs curb resistance. Healthcare Benchmarks
Qual Improv 2008, 15(11):114–5.
25. Dos Santos RP, Magedanz L, Siliprandi EM: Antimicrobial stewardship
programs must apply to all. Infect Control Hosp Epidemiol 2009,
30(2):205–207.
26. Drew RH: Antimicrobial stewardship programs: how to start and steer a
successful program. J Manag Care Pharm 2009, 15(2 Suppl):S18–S23.
27. Mertz D, Koller M, Haller P, Lampert ML, Plagge H, Hug B, et al: Outcomes
of early switching from intravenous to oral antibiotics on medical wards.
J Antimicrob Chemother 2009, 64(1):188–199.
28. Barth J, Stauch K, Landen H: Efficacy and tolerability of sequential
intravenous/oral moxifloxacin therapy in pneumonia: results of the first
post-marketing surveillance study with intravenous moxifloxacin in
hospital practice. Clin Drug Investig 2005, 25(11):691–700.
29. Pelly L: IV-to-oral switch therapy for community-acquired pneumonia
requiring hospitalization: focus on gatifloxacin. Adv Ther 2002,
19(5):229–242.
30. Furlanut M, Brollo L, Lugatti E, Di Qual E, Dolcet F, Talmassons G, et al:
Pharmacokinetic aspects of levofloxacin 500 mg once daily during
sequential intravenous/oral therapy in patients with lower respiratory
tract infections. J Antimicrob Chemother 2003, 51(1):101–106.
doi:10.1186/1471-2334-12-159
Cite this article as: Ramirez et al.: Switch therapy in hospitalized patients
with community-acquired pneumonia: Tigecycline vs. Levofloxacin. BMC
Infectious Diseases 2012 12:159.
Submit your next manuscript to BioMed Central
and take full advantage of: 
• Convenient online submission
• Thorough peer review
• No space constraints or color ﬁgure charges
• Immediate publication on acceptance
• Inclusion in PubMed, CAS, Scopus and Google Scholar
• Research which is freely available for redistribution
Submit your manuscript at 
www.biomedcentral.com/submit
Ramirez et al. BMC Infectious Diseases 2012, 12:159 Page 7 of 7
http://www.biomedcentral.com/1471-2334/12/159
